Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses

Further Supporting the Therapeutic Potential of HspE7

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. HPV 16 E7-specific T-cell responses were elicited in all four subjects in the study's third cohort following administration of 500 mcg of HspE7 and 1,000 mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. All T-cell responses represented significant changes from baseline, indicating that the responses were a direct result of treatment with HspE7. As previously announced, three out of four of the patients in cohort 2 (administered 500 mcg of HspE7 and 500 mcg of Poly-ICLC) demonstrated a T-cell response, which may validate that HspE7 is more active with an elevated dose of adjuvant.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We continue to be very encouraged with the immunological results from our Phase 1 HspE7 trial as they demonstrate that administration of HspE7 induces T-cell responses that we believe to be therapeutic," said Gregory M. McKee, president and chief executive officer at Nventa. "These positive immunological data, along with the safety data analyzed to date, provide a strong foundation for our Phase 2 trial expected to begin mid-2008."

Independent research findings recently published in the journal Gynecologic Oncology by Jeffrey Weber, M.D., Ph.D., associate director for clinical research at the University of Southern California's Norris Comprehensive Cancer Center, demonstrated that such an immune response may be associated with objective c
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... Oct. 20, 2014   Taiho Oncology, Inc. ... ( Japan ), announced that the ... Track designation for TAS-102 (nonproprietary names: trifluridine and ... investigation for the treatment of refractory metastatic colorectal ... a rolling NDA submission to the FDA. According ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... 20, 2014 ASCNYC (ascnyc.org) is ... helps New Yorkers living with HIV/AIDS and other ... housing, recovery and self-sufficiency. Each year, ASCNYC spotlights ... community through their tireless efforts. , Savills ... , has been selected as this year’s honoree ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... , SAN FRANCISCO, CA February 2, 2010 -- ... coronary heart disease worldwide, only some obese individuals go ... relatively protected. Defining these protective factors could help scientists ... this end, a research team at the Gladstone Institute ...
... , , KNOXVILLE, Tenn. , ... TMH ), one of the largest suppliers of outsourced healthcare ... in the United States , today announced that the Company ... the market closes on Tuesday, February 9, 2010 , to ...
... , SAN DIEGO , Feb. 3 For ... the top 100 integrated health care networks in the nation in an ... was ranked No. 6 in the nation and No. 1 in ... Modern Healthcare , is regarded as the nation,s premier rating system for ...
... , , TUCSON, Ariz. , ... ) today announced that Fletcher McCusker , Chairman and Chief Executive ... the UBS 20th Annual Global Healthcare Services Conference on Wednesday, February ... .   , Providence ,s presentation is scheduled for 10:00 ...
... , ... FDA is alerting the public about the following products: , ... Alli, 60 mg capsules (120-count refill kit) sold over the Internet ... Insulin Syringes may have needles that detach from the syringe and ...
... , MT. LAUREL, N.J. , Feb. ... transcription software and services, today announced that it has agreed ... provider of clinical documentation technology and services that recently filed ... place pursuant to Section 363 of the United States Bankruptcy ...
Cached Medicine News:Health News:Gladstone scientists identify target that may reduce complications of obesity 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 3Health News:Sharp HealthCare Rated Top Health Care Network in California and No. 6 in the Nation 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 3Health News:FDA Consumer Health Information - FDA's MedWatch Safety Alerts: January 2010 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 3
Inquire...
... Calf Implants are available ... sizes. They are available non-sterile ... and sold individually. Depending on ... may use one or two ...
... the IQmark family elevates your ECG and Spirometry ... cost-savings and efficient patient care. The IQmark Diagnostic ... office, clinics and medical centers as well as ... in conjunction with the IQmark Digital ECG PDA ...
... data-gathering extension of the IQmark Diagnostic Workstation, ... Windows-based PC to deliver unmatched speed, accuracy ... Now you can download and seamlessly integrate ... simple click of a mouse. The point-and-click ...
Medicine Products: